U.S. Markets closed

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.83+0.02 (+0.42%)
At close: 4:00PM EDT

4.87 0.04 (0.83%)
After hours: 4:41PM EDT

People also watch
Full screen
Previous Close4.81
Bid4.81 x 100
Ask4.88 x 300
Day's Range4.81 - 4.88
52 Week Range2.06 - 5.18
Avg. Volume114,007
Market Cap90.49M
PE Ratio (TTM)-18.09
EPS (TTM)-0.27
Earnings DateAug 9, 2017 - Aug 14, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS

    HACKENSACK, N.J. and PETACH TIKVA, Israel, July 25, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the University of California Irvine Medical Center (UCI) to enroll patients in the planned Phase 3 clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals. Dr. Namita Goyal has agreed to participate as Principal Investigator at UCI.

  • Zacks Small Cap Research2 days ago

    BCLI: Receives $16 Million Grant From CIRM to Fund Phase 3 Trial in ALS

    On July 21, 2017, BrainStorm (BCLI) announced that the company has received a $16 million grant from the California Institute for Regenerative Medicine (CIRM) to help fund the company’s upcoming Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS).  CIRM was established in 2004 through Proposition 71: the California Stem Cell Research and Cures Initiative. While CIRM initially concerned itself with supporting scientists who were just entering the stem cell field, the organization has recently launched CIRM 2.0, which aims to make funding available sooner for projects that are likely to bring stem cell therapies to patients with unmet medical needs (e.g., late stage clinical trials).

  • PR Newswire6 days ago

    Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS

    The grant from CIRM is a significant endorsement of the potential for Brainstorm's novel approach to treat ALS using adult stem cells. CIRM is the World's Largest Institution Dedicated to Cell Therapies. "We are honored to be awarded this CIRM grant, and appreciate the support of CIRM in the development of NurOwn," said Chaim Lebovits, President and CEO of Brainstorm.